• ¿Documento equivocado? Cámbialo gratis
  • Escrito por estudiantes que aprobaron
  • Inmediatamente disponible después del pago
  • Leer en línea o como PDF
Vender
¿Dónde estudias?
Tu idioma
Document preview thumbnail
Vista previa 4 fuera de 35 páginas
Examen

NURS 6512 Final Exam | NURS 6512 Advanced Pharmacology | Actual Q&A with Rationale (NURS 6512 Final Exam) | Walden

Document preview thumbnail
Vista previa 4 fuera de 35 páginas

NURS 6512 Final Exam | NURS 6512 Advanced Pharmacology | Actual Q&A with Rationale (NURS 6512 Final Exam) | Walden

Vista previa del contenido

NURS 6512 Final Exam | NURS 6512 Advanced
Pharmacology | Actual Q&A with Rationale (NURS
6512 Final Exam) | Walden

Section A: Neurology & Psychiatric Drugs (Questions 1–20)

Q1. A patient with major depressive disorder is started on a selective serotonin
reuptake inhibitor (SSRI). Which mechanism of action best describes how SSRIs
improve mood?


A. Blockade of dopamine reuptake

B. Inhibition of serotonin reuptake into the presynaptic neuron ✅

C. Antagonism of serotonin receptors

D. Inhibition of monoamine oxidase

Rationale: SSRIs work by blocking the serotonin transporter (SERT) on the presynaptic
neuron, which increases the concentration of serotonin in the synaptic cleft. This
enhanced serotonergic activity is thought to improve mood, anxiety, and obsessive-
compulsive symptoms over several weeks. Unlike MAOIs, SSRIs do not inhibit
monoamine oxidase, and they have minimal effect on dopamine or norepinephrine
reuptake.
Q2. A patient on an SSRI develops serotonin syndrome after adding a second
serotonergic drug. Which of the following is a hallmark symptom of serotonin
syndrome?


A. Hypothermia and bradycardia

B. Hyperthermia, clonus, and agitation ✅

,C. Dry mouth and urinary retention

D. Sedation and hypotension

Rationale: Serotonin syndrome is a potentially life-threatening condition caused by
excessive serotonergic activity, often from combining SSRIs, MAOIs, or other
serotonergic agents. Key features include hyperthermia, muscle clonus, hyperreflexia,
agitation, and autonomic instability. Treatment involves discontinuing the offending
agents and providing supportive care, including benzodiazepines for agitation.
Q3. Which antipsychotic is most likely to cause extrapyramidal symptoms (EPS) due to
strong D2 blockade?


A. Clozapine

B. Quetiapine

C. Haloperidol ✅

D. Olanzapine

Rationale: Haloperidol is a first-generation (typical) antipsychotic with high affinity for
dopamine D2 receptors in the striatum, which directly correlates with a high risk of EPS.
EPS include acute dystonia, parkinsonism, akathisia, and tardive dyskinesia, caused by
excessive dopamine blockade. Second-generation antipsychotics like clozapine and
quetiapine have lower D2 affinity and higher serotonin blockade, reducing EPS risk but
increasing metabolic side effects.
Q4. A patient with bipolar disorder is started on lithium. Which of the following requires
regular monitoring during lithium therapy?


A. Liver function tests

B. Serum lithium levels, renal function, and thyroid function ✅

C. Complete blood count only

D. Electrocardiogram only

,Rationale: Lithium has a narrow therapeutic index (0.6–1.2 mEq/L), and levels above 1.5
mEq/L can cause toxicity, including nausea, tremor, ataxia, and seizures. Chronic lithium
use can impair renal concentrating ability and cause hypothyroidism, so serum
creatinine, TSH, and lithium levels must be monitored regularly. Dehydration, NSAIDs,
and diuretics can increase lithium levels, so patient education is critical.
Q5. Which anticonvulsant is a first-line treatment for trigeminal neuralgia?


A. Phenytoin

B. Gabapentin

C. Carbamazepine ✅

D. Valproic acid

Rationale: Carbamazepine is the drug of choice for trigeminal neuralgia because it
stabilizes neuronal membranes by blocking sodium channels, reducing the frequency of
pain paroxysms. Gabapentin and pregabalin are also used for neuropathic pain but are
not first-line for trigeminal neuralgia. Carbamazepine requires monitoring of CBC, liver
function, and serum levels due to its narrow therapeutic index and risk of
agranulocytosis.
Q6. A patient with generalized anxiety disorder is prescribed buspirone. Which
statement about buspirone is correct?


A. It has a rapid onset of action within 24 hours

B. It is a partial agonist at serotonin 5-HT1A receptors ✅

C. It is contraindicated with SSRIs

D. It causes significant sedation and dependence

Rationale: Buspirone is a partial agonist at serotonin 5-HT1A receptors, which reduces
anxiety without the sedation, dependence, or withdrawal seen with benzodiazepines. Its
onset of action is delayed, typically taking 2–4 weeks to achieve full therapeutic effect,

, similar to antidepressants. Buspirone is safe to combine with SSRIs and has no abuse
potential, making it a good option for chronic anxiety.
Q7. Which of the following is a contraindication to using clozapine?


A. History of hypertension

B. History of agranulocytosis ✅

C. History of diabetes

D. History of obesity

Rationale: Clozapine is associated with a significant risk of agranulocytosis (1–2% of
patients), which requires regular absolute neutrophil count (ANC) monitoring. It is
contraindicated in patients with a history of clozapine-induced agranulocytosis or
severe neutropenia. Despite this risk, clozapine is the most effective antipsychotic for
treatment-resistant schizophrenia and is also used to reduce suicidal behavior.
Q8. A patient on phenytoin develops nystagmus, ataxia, and slurred speech. These
symptoms most likely indicate:


A. Allergic reaction

B. Phenytoin toxicity ✅

C. Therapeutic effect

D. Drug interaction with food

Rationale: Phenytoin has nonlinear pharmacokinetics; small dose increases can cause
disproportionate rises in serum levels, leading to toxicity. Symptoms of phenytoin
toxicity include nystagmus, ataxia, dysarthria, and sedation, which correlate with serum
levels above 20 mcg/mL. Management involves holding the dose, checking serum level,
and adjusting the dose based on therapeutic drug monitoring.
Q9. Which antidepressant is most appropriate for a patient with depression and

Información del documento

Subido en
18 de agosto de 2026
Número de páginas
35
Escrito en
2026/2027
Tipo
Examen
Contiene
Preguntas y respuestas
$17.99

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Seller avatar
Los indicadores de reputación están sujetos a la cantidad de artículos vendidos por una tarifa y las reseñas que ha recibido por esos documentos. Hay tres niveles: Bronce, Plata y Oro. Cuanto mayor reputación, más podrás confiar en la calidad del trabajo del vendedor.
ScholarsAscend
3.7
(83)
Vendido
516
Seguidores
40
Artículos
30538
Última venta
5 horas hace




Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes